A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Nuvation Bio Inc. NUVB

Promising (early) broader-coverage candidate · Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost e

On FrontierLab's discovery record since 2026-07-01 (13 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-18), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)	1083.6%
Gross margin	93.9%
Gross profits / assets	0.21
Rule of 40	1002.6
Net margin	-81%
Cash runway (months)	96
PEG	—
Price / sales	12.4

Quality checklist

✓ Revenue growth — 1083.6% (pass ≥ 20%)
✓ Capital efficiency
✓ Gross margin — 93.9% (pass ≥ 60%)
✓ Gross-margin trend — 66.4 (pass ≥ 2)
✓ Share dilution — 2.4%

Fundamentals — snapshot as of 2026-09-18

Stage	Early
Share issuance (YoY)	2.4% · modest issuance
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-0.44
Burn multiple	0.5
Gross-margin trend (pts)	66.4
Cash / assets	0.89
Net debt / EBITDA	—
Statements as of	Q2 FY2026 · filed 2026-08-06

Momentum context — a snapshot from 2026-09-18, not current

Price at surface	$6.07 (as of 2026-09-18)
52-week range	$2.99 – $9.75
% off 52-wk high	-37.7%
RSI (14)	43
Relative volume	1.2×

Risk flags

Burning cash — operating margin is negative.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-09-18 (end-of-day). How grades are computed →